Details of the Drug

General Information of Drug (ID: DMB0FWL)

Drug Name

Dihydrocodeine

Synonyms

Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Common cold	CA00	Approved	[1]
Cough	MD12	Approved	[1]
Pain	MG30-MG3Z	Approved	[1]
Rhinitis	FA20	Approved	[1]
Cancer related pain	MG30	Phase 4	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

301.4

Logarithm of the Partition Coefficient (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 4.21 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4 hours [3]
Metabolism: The drug is metabolized via the liver []
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.07 L/kg [3]

Chemical Identifiers

Formula: C18H23NO3
IUPAC Name: (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
Canonical SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O
InChI: InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
InChIKey: RBOXVHNMENFORY-DNJOTXNNSA-N

Cross-matching ID

PubChem CID: 5284543
ChEBI ID: CHEBI:135276
CAS Number: 125-28-0
DrugBank ID: DB01551
TTD ID: D0T6RC
INTEDE ID: DR0500

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Modulator	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[6]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[7]
UDP-glucuronosyltransferase 2B4 (UGT2B4)	DENUPDX	UD2B4_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dihydrocodeine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Levomilnacipran.	Chronic pain [MG30]	[8]
-----------

Coadministration of a Drug Treating the Disease Different from Dihydrocodeine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Dihydrocodeine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[9]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Oliceridine.	Acute pain [MG31]	[10]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Dihydrocodeine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[11]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Cariprazine.	Bipolar disorder [6A60]	[10]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Dihydrocodeine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Dihydrocodeine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[13]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Dihydrocodeine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[14]
Vilazodone	DM4LECQ	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Vilazodone.	Depression [6A70-6A7Z]	[8]
Vortioxetine	DM6F1PU	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Vortioxetine.	Depression [6A70-6A7Z]	[15]
Milnacipran	DMBFE74	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Milnacipran.	Depression [6A70-6A7Z]	[8]
Desvenlafaxine	DMHD4PE	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Desvenlafaxine.	Depression [6A70-6A7Z]	[8]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Dihydrocodeine and OPC-34712.	Depression [6A70-6A7Z]	[10]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Esketamine.	Depression [6A70-6A7Z]	[16]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Mepenzolate.	Digestive system disease [DE2Z]	[17]
5-hydroxy-L-tryptophan	DMDWZGJ	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[8]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Dihydrocodeine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Dihydrocodeine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[9]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Dihydrocodeine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Dihydrocodeine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[20]
Solifenacin	DMG592Q	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Solifenacin.	Functional bladder disorder [GC50]	[17]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Dihydrocodeine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[21]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Dihydrocodeine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[22]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Dihydrocodeine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Belladonna	DM2RBWK	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[17]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Dihydrocodeine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[23]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Suvorexant.	Insomnia [7A00-7A0Z]	[10]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Tasimelteon.	Insomnia [7A00-7A0Z]	[10]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Paraldehyde.	Insomnia [7A00-7A0Z]	[10]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Dihydrocodeine and ITI-007.	Insomnia [7A00-7A0Z]	[10]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Quazepam.	Insomnia [7A00-7A0Z]	[10]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Dihydrocodeine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[24]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[10]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Dihydrocodeine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[9]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Dihydrocodeine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[25]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Dihydrocodeine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[9]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Dihydrocodeine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Dihydrocodeine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Dihydrocodeine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[27]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Dihydrocodeine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[28]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Dihydrocodeine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[25]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Lasmiditan.	Migraine [8A80]	[16]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Dihydrocodeine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[29]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Flibanserin.	Mood disorder [6A60-6E23]	[16]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Dihydrocodeine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[30]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Dihydrocodeine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Dihydrocodeine due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[32]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Dihydrocodeine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[33]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Pimavanserin.	Parkinsonism [8A00]	[10]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dihydrocodeine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[34]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Methylscopolamine.	Peptic ulcer [DA61]	[35]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Dihydrocodeine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[36]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Dihydrocodeine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[37]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Dihydrocodeine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[19]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Iloperidone.	Schizophrenia [6A20]	[10]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Molindone.	Schizophrenia [6A20]	[10]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Thiothixene.	Schizophrenia [6A20]	[10]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Asenapine.	Schizophrenia [6A20]	[10]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Dihydrocodeine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[30]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Dihydrocodeine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[19]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Dihydrocodeine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Armodafinil	DMGB035	Minor	Increased metabolism of Dihydrocodeine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
LEE011	DMMX75K	Moderate	Decreased metabolism of Dihydrocodeine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[39]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Dihydrocodeine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[9]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Dihydrocodeine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[40]
Brilinta	DMBR01X	Moderate	Altered absorption of Dihydrocodeine due to GI dynamics variation caused by Brilinta.	Thrombosis [DB61-GB90]	[32]
-----------


⏷ Show the Full List of 66 DDI Information of This Drug

References

1	Caffeine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7594).
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
5	Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
6	The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
7	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
8	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
11	Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
12	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
13	Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83. [PMID: 9834039]
14	Product Information. Prevymis (letermovir). Merck &amp Company Inc, Whitehouse Station, NJ.
15	Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5. [PMID: 18171260]
16	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
17	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
18	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
19	Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
20	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
21	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
22	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
23	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
24	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
25	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
26	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
27	Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10. [PMID: 9723817]
28	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
29	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
30	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
31	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
32	Cerner Multum, Inc. "Australian Product Information.".
33	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
34	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
35	Product Information. Lortab (acetaminophen-hydrocodone). Akorn Inc, Buffalo Grove, IL.
36	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
37	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
38	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
39	Kane GC, Lipsky JJ "Drug-grapefruit juice interactions." Mayo Clin Proc 75 (2000): 933-42. [PMID: 10994829]
40	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.